Old Web
English
Sign In
Acemap
>
authorDetail
>
Bhargava Kandala
Bhargava Kandala
Merck & Co.
Medicine
Pharmacokinetics
Regimen
Reverse-transcriptase inhibitor
Anesthesia
6
Papers
31
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Single oral doses of MK-8507, a novel non-nucleoside reverse transcriptase inhibitor, suppress HIV-1 RNA for a week
2021
Journal of Acquired Immune Deficiency Syndromes
Dirk Schürmann
Deanne Jackson Rudd
Andrea K. Schaeffer
Inge De Lepeleire
Evan J. Friedman
Martine Robberechts
Saijuan Zhang
Yang Liu
Bhargava Kandala
Christian Keicher
Martin Daumer
Jörg Hofmann
Jay A. Grobler
S. Aubrey Stoch
Marian Iwamoto
Wendy Ankrom
Show All
Source
Cite
Save
Citations (1)
ModVizPop: A shiny interface for empowering teams to perform interactive pharmacokinetic/pharmacodynamic simulations.
2021
Pavan Vaddady
Bhargava Kandala
Show All
Source
Cite
Save
Citations (0)
Population Pharmacokinetic and Pharmacodynamic Analysis to Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
2020
Antimicrobial Agents and Chemotherapy
Pavan Vaddady
Bhargava Kandala
Ka Lai Yee
Show All
Source
Cite
Save
Citations (1)
Clinical Evaluation of MK‐2640: An Insulin Analog With Glucose‐Responsive Properties
2019
Clinical Pharmacology & Therapeutics
Alexander W. Krug
Sandra A.G. Visser
Kuenhi Tsai
Bhargava Kandala
Craig Fancourt
Bob Thornton
Linda Morrow
Niels C. Kaarsholm
Harold S. Bernstein
S. Aubrey Stoch
Michael F. Crutchlow
David E. Kelley
Marian Iwamoto
Show All
Source
Cite
Save
Citations (17)
A model‐informed drug discovery and development (MID3) strategy for the novel glucose‐responsive insulin MK‐2640 enabled rapid decision making
2019
Clinical Pharmacology & Therapeutics
Sandra A.G. Visser
Bhargava Kandala
Craig Fancourt
Alexander W. Krug
Carolyn R. Cho
Show All
Source
Cite
Save
Citations (9)
1